Teleflex Inc (TFX) — SEC Filings
Teleflex Inc (TFX) — 34 SEC filings. Latest: 10-Q (May 7, 2026). Includes 12 8-K, 10 SC 13G/A, 7 10-Q.
View Teleflex Inc on SEC EDGAR
Overview
Teleflex Inc (TFX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Teleflex Inc. (TFX) reported a significant net loss of $408.89 million for the three months ended September 28, 2025, a stark contrast to the net income of $111.00 million in the prior-year period. This loss was primarily driven by a substantial goodwill impairment charge of $403.93 million and rest
Sentiment Summary
Across 34 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 32 neutral. The dominant filing sentiment for Teleflex Inc is neutral.
Filing Type Overview
Teleflex Inc (TFX) has filed 7 10-Q, 12 8-K, 1 DEFA14A, 2 DEF 14A, 2 10-K, 10 SC 13G/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (34)
Risk Profile
Risk Assessment: Of TFX's 24 recent filings, 1 were flagged as high-risk, 6 as medium-risk, and 17 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $913.02M |
| Net Income | -$408.89M |
| EPS | -$9.24 |
| Total Debt | $2.57B |
Industry Context
The medical device industry is characterized by intense competition, rapid technological advancements, and significant regulatory oversight. Companies like Teleflex compete across various segments, including cardiovascular, urology, and surgical. Recent consolidation, such as Teleflex's acquisition of BIOTRONIK's Vascular Intervention business, highlights a trend towards strategic M&A to gain market share and expand product portfolios.
Top Tags
institutional-ownership (5) · amendment (5) · Medical Devices (4) · 10-Q (4) · financials (4) · medical-devices (4) · sec-filing (3) · Teleflex Inc. (3) · Healthcare Sector (2) · quarterly-report (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $408.89M | For Q3 2025, a significant swing from $111.00M net income in Q3 2024. |
| Net Revenues | $913.02M | Increased by 19.45% for Q3 2025 compared to Q3 2024. |
| Goodwill Impairment Charge | $403.93M | Major contributor to the net loss in Q3 2025. |
| Restructuring Charges | $117.62M | Significant increase from $0.29M in Q3 2024, impacting profitability. |
| Interventional Product Revenue | $266.41M | Increased by 77.77% in Q3 2025, driven by the BIOTRONIK acquisition. |
| Long-term Borrowings | $2.57B | Increased from $1.56B at Dec 31, 2024, primarily for the BIOTRONIK acquisition. |
| BIOTRONIK Acquisition Cost | $825.2M | Net initial cash payment for the Vascular Intervention business. |
| Net Cash from Operations | $188.97M | Decreased from $435.62M for the nine months ended Sep 28, 2024. |
| Diluted EPS | -$9.24 | For Q3 2025, a significant drop from $2.36 in Q3 2024. |
| Shares Outstanding | 44,194,408 | As of November 4, 2025. |
| Net Income for Q2 2025 | $105.2M | Increased from $88.7 million in Q2 2024, representing an 18.6% increase. |
| Net Income for H1 2025 | $201.5M | Increased from $170.1 million in H1 2024. |
| Total Assets as of June 29, 2025 | $6.89B | Increased from $6.85 billion at December 31, 2024. |
| Retained Earnings as of June 29, 2025 | $3.11B | Increased from $3.01 billion at December 31, 2024. |
| Percentage increase in Q2 Net Income | 18.6% | Reflects growth from $88.7 million in Q2 2024 to $105.2 million in Q2 2025. |
Forward-Looking Statements
- {"claim":"Janus Henderson Group plc will maintain a significant stake in Teleflex Incorporated throughout 2024.","entity":"Janus Henderson Group plc","targetDate":"2024-12-31","confidence":"medium"}
- {"claim":"Vanguard will continue to hold a significant, albeit potentially fluctuating, stake in Teleflex Inc. as part of its index-tracking and diversified portfolios.","entity":"The Vanguard Group","targetDate":"December 31, 2024","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Teleflex Inc (TFX)?
Teleflex Inc has 34 recent SEC filings from Jan 2024 to May 2026, including 12 8-K, 10 SC 13G/A, 7 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TFX filings?
Across 34 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 32 neutral. The dominant sentiment is neutral.
Where can I find Teleflex Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Teleflex Inc (TFX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Teleflex Inc?
Key financial highlights from Teleflex Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for TFX?
The investment thesis for TFX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Teleflex Inc?
Executive information for Teleflex Inc is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Teleflex Inc stock?
Of TFX's 24 assessed filings, 1 were flagged high-risk, 6 medium-risk, and 17 low-risk.
What are recent predictions and forward guidance from Teleflex Inc?
Recent forward-looking statements from Teleflex Inc include guidance on {"claim":"Janus Henderson Group plc will maintain a significant stake in Teleflex Incorporated throughout 2024.","entity and 1 other predictions.